Bloom Burton Estimates BioSyent’s FY2026 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Bloom Burton reduced their FY2026 earnings estimates for BioSyent in a note issued to investors on Monday, March 17th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.88 per share for the year, down from their prior forecast of $0.91. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share.

BioSyent Stock Performance

CVE RX opened at C$11.23 on Wednesday. The stock has a market cap of C$128.44 million, a P/E ratio of 18.23 and a beta of 0.93. The company’s 50-day simple moving average is C$11.03 and its 200 day simple moving average is C$11.11. BioSyent has a twelve month low of C$8.24 and a twelve month high of C$12.13. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90.

Insider Activity at BioSyent

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. 33.65% of the stock is currently owned by insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.